ASND on Nasdaq

Ascendis Pharma A/S

Ascendis Pharma A/S is a pharmaceutical preparations company, listed on Nasdaq (ASND).1

Price unavailable

Last updated Oct 20, 2026.

Overview

720.1MRevenue, fiscal 20252
-228.0MNet income, fiscal 20252

Compare with Evotec, Galápagos NV or Morphosys, or pick any stock.

  • TickerASND on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersG71
  • Incorporated inDenmark3
  • Business addressTuborg Boulevard 12, Hellerup3
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

As used herein, references to “we”, “us”, the “company”, “Ascendis”, or “Ascendis Pharma”, or similar terms in this annual report on Form 20-F shall mean Ascendis Pharma A/S and, as the context requires, its subsidiaries.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

86.8%Gross margin2
-18.9%Operating margin2
-31.7%Net margin2
98.0%Revenue growth, 20252

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue10¢94.9M EUR
  • Research and development32¢303.6M EUR
  • Selling, general and admin48¢457.9M EUR
  • Interest8¢80.6M EUR
  • Income tax2¢15.4M EUR

Out of 720.1M EUR in revenue.2 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Share buybacks32¢17.4M EUR
  • Kept or used elsewhere68¢36.5M EUR

Out of 53.9M EUR of cash from operations.2

Financial statements

Revenue567892720.1M EUR in 2025+6706% since 2018
0200.0M EUR400.0M EUR600.0M EUR800.0M EUR2018: 10.6M EUR10.6M EUR20182019: 13.4M EUR13.4M EUR2019+26%2020: 7.0M EUR7.0M EUR2020−48%2021: 7.8M EUR7.8M EUR2021+12%2022: 51.2M EUR51.2M EUR2022+558%2023: 266.7M EUR266.7M EUR2023+421%2024: 363.6M EUR363.6M EUR2024+36%2025: 720.1M EUR720.1M EUR2025+98%
Gross profit67892625.2M EUR in 2025+4575% since 2019
0200.0M EUR400.0M EUR600.0M EUR800.0M EUR2019: 13.4M EUR13.4M EUR20192020: 7.0M EUR7.0M EUR2020−48%2021: 4.3M EUR4.3M EUR2021−39%2022: 39.0M EUR39.0M EUR2022+817%2023: 222.3M EUR222.3M EUR2023+470%2024: 319.4M EUR319.4M EUR2024+44%2025: 625.2M EUR625.2M EUR2025+96%
Operating income567892-136.3M EUR in 2025−12% since 2018
-600.0M EUR-400.0M EUR-200.0M EUR02018: -154.8M EUR-154.8M EUR20182019: -226.7M EUR-226.7M EUR2019+46%2020: -330.6M EUR-330.6M EUR2020+46%2021: -451.8M EUR-451.8M EUR2021+37%2022: -561.8M EUR-561.8M EUR2022+24%2023: -455.5M EUR-455.5M EUR2023−19%2024: -278.8M EUR-278.8M EUR2024−39%2025: -136.3M EUR-136.3M EUR2025−51%
Net income567892-228.0M EUR in 2025+75% since 2018
-600.0M EUR-400.0M EUR-200.0M EUR02018: -130.1M EUR-130.1M EUR20182019: -218.0M EUR-218.0M EUR2019+68%2020: -419.0M EUR-419.0M EUR2020+92%2021: -383.6M EUR-383.6M EUR2021−8%2022: -583.2M EUR-583.2M EUR2022+52%2023: -481.4M EUR-481.4M EUR2023−17%2024: -378.1M EUR-378.1M EUR2024−21%2025: -228.0M EUR-228.0M EUR2025−40%
Fiscal year20182019202020212022202320242025
Revenue10.6M EUR513.4M EUR67.0M EUR77.8M EUR851.2M EUR9266.7M EUR2363.6M EUR2720.1M EUR2
Cost of revenue3.5M EUR812.1M EUR944.4M EUR244.3M EUR294.9M EUR2
Gross profit13.4M EUR67.0M EUR74.3M EUR839.0M EUR9222.3M EUR2319.4M EUR2625.2M EUR2
Research and development295.9M EUR8379.6M EUR9413.5M EUR2307.0M EUR2303.6M EUR2
Selling, general and admin160.2M EUR8221.2M EUR9264.4M EUR2291.1M EUR2457.9M EUR2
Operating income-154.8M EUR5-226.7M EUR6-330.6M EUR7-451.8M EUR8-561.8M EUR9-455.5M EUR2-278.8M EUR2-136.3M EUR2
Interest3.9M EUR830.7M EUR944.1M EUR265.5M EUR280.6M EUR2
Income before tax-383.9M EUR8-577.8M EUR9-474.1M EUR2-373.2M EUR2-212.7M EUR2
Income tax-367.0K EUR85.4M EUR97.3M EUR24.8M EUR215.4M EUR2
Net income-130.1M EUR5-218.0M EUR6-419.0M EUR7-383.6M EUR8-583.2M EUR9-481.4M EUR2-378.1M EUR2-228.0M EUR2
Earnings per share-7 EUR/shares8-10 EUR/shares9-9 EUR/shares2-7 EUR/shares2-4 EUR/shares2
Earnings per share (diluted)-7 EUR/shares8-10 EUR/shares9-9 EUR/shares2-7 EUR/shares2-4 EUR/shares2
Shares (weighted, basic)54.8M shares856.1M shares956.3M shares257.9M shares260.6M shares2

Compare Ascendis Pharma A/S with another company

Corporate structure

Ascendis Pharma A/S sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Ascendis Pharma A/S

  • Artisan Partners Limited Partnership Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest Aug 13, 2026 (6 filings since Feb 4, 2022)
  • Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest May 15, 2026 (9 filings since Feb 10, 2022)
  • Capital International Investors Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest May 14, 2026 (2 filings since Aug 13, 2025)
  • T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest May 7, 2026 (7 filings since Feb 14, 2024)
  • FMR LLC Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest May 6, 2026 (5 filings since Feb 9, 2022)
  • WESTFIELD CAPITAL MANAGEMENT CO LP Filed SCHEDULE 13G/A on Ascendis Pharma A/S, latest Feb 11, 2026 (5 filings since Feb 2, 2023)
  • Avoro Capital Advisors LLC Filed SC 13G/A on Ascendis Pharma A/S, latest Nov 14, 2024 (3 filings since Feb 14, 2023)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Ascendis Pharma A/S, latest Nov 14, 2024 (5 filings since Feb 14, 2022)
  • Wellington Management Company Filed SC 13G/A on Ascendis Pharma A/S, latest Nov 8, 2024 (4 filings since Feb 4, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Ascendis Pharma A/S, latest Feb 16, 2024 (4 filings since Feb 14, 2022)
  • BAKER BROS. ADVISORS LP Filed SC 13G/A on Ascendis Pharma A/S, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Ascendis Pharma A/S G7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Ascendis Pharma A/S reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net146.5M EUR2 Dec 31, 202598.7M EUR2 Dec 31, 2024+48.4%
Operating-lease assets (leased space)30.9M EUR2 Dec 31, 202511.2M EUR9 Dec 31, 2024+175.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents616.0M EUR2 Dec 31, 2025559.5M EUR2 Dec 31, 2024+10.1%
Long-term investments10.9M EUR2 Dec 31, 20252.3M EUR2 Dec 31, 2024+369.1%

Inventory

ItemLatestA year beforeChange
Inventory, total301.5M EUR2 Dec 31, 2025295.6M EUR2 Dec 31, 2024+2.0%
Raw materials19.1M EUR2 Dec 31, 202517.6M EUR2 Dec 31, 2024+8.5%

Leadership

Who has led Ascendis Pharma A/S, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (13)

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.17) a share, on Nov 12, 2025.25

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

433 filings to the SEC since October 2021: 5 annual reports, 25 insider forms, 53 large holders, 350 other. The latest 20:

  1. Oct 14, 20266-K EDGAR
  2. Sep 29, 20266-K EDGAR
  3. Sep 28, 20264 EDGAR
  4. Sep 15, 20266-K EDGAR
  5. Sep 15, 20266-K EDGAR
  6. Sep 9, 20264 EDGAR
  7. Sep 9, 20266-K EDGAR
  8. Sep 9, 20266-K EDGAR
  9. Sep 8, 2026144 EDGAR
  10. Sep 3, 20264 EDGAR
  11. Sep 2, 2026144 EDGAR
  12. Aug 31, 20266-K EDGAR
  13. Aug 18, 20264 EDGAR
  14. Aug 13, 20266-K EDGAR
  15. Aug 13, 2026SCHEDULE 13G/A EDGAR
  16. Aug 13, 20266-K EDGAR
  17. Aug 12, 20266-K EDGAR
  18. Aug 6, 20266-K EDGAR
  19. Jul 15, 20266-K EDGAR
  20. Jun 30, 20266-K EDGAR

The 433 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 5 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 8, 2026Bodenhoff MadsSVP & PAOSale3,000$270.19$810.6KForm 4
Sep 2, 2026HOLTUG LARSDirectorSale236$264.13$62.3KForm 4
Aug 14, 2026BIENAIME JEAN JACQUESDirectorBuy2,000$246.33$492.7KForm 4
Jun 2, 2026SMITH SCOTT THOMASEVP & Chief Financial OfficerBuy100$219.00$21.9KForm 4
May 29, 2026BIENAIME JEAN JACQUESDirectorBuy500$223.12$111.6KForm 4
May 29, 2026SMITH SCOTT THOMASEVP & Chief Financial OfficerBuy250$223.32$55.8KForm 4
May 26, 2026BIENAIME JEAN JACQUESDirectorBuy400$237.81$95.1KForm 4
May 11, 2026JENSEN FLEMMING STEENSee RemarksSale19,460$238.49$4.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Ascendis Pharma A/S is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAscendis Pharma A/S1
  • CIK0001612042
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inThe Kingdom of Denmark4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressTuborg Boulevard 12, Hellerup, Denmark1
  • Phone45 70 22 22 441
  • Shares outstanding61,977,408 shares as of Dec 31, 20254
  • AuditorDeloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark PCAOB ID 1294; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceAug 1, 20141
  • Filings793 in all: 6-K (429), 144 (113), SC 13G/A (60), SC 13D/A (24), 424B5 (16), SCHEDULE 13G/A (16), 3 (15), S-8 (14)1
    All 37 form types

    SC 13G (13), 20-F (12), CORRESP (12), UPLOAD (11), 4 (9), CT ORDER (5), EFFECT (5), SD (5), SC 13D (4), F-3 (3), F-3ASR (3), SCHEDULE 13G (3), 144/A (2), DRS/A (2), DRSLTR (2), F-1/A (2), 3/A (1), 424B4 (1), 6-K/A (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), D (1), DRS (1), F-1 (1), F-1MEF (1), F-3MEF (1), F-6 (1), FWP (1)

  • Latest filingsAnnual report (20-F) Feb 11, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary SharesThe Nasdaq Stock Market LLC
Ordinary sharesASNDThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Feb 11, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36